Abstract:(a) In the skin fibroblasts are a key source of SASP production, with melanocytes having significantly less production. In healthy individuals, senescent fibroblasts play a major role in attracting T cells from the circulation by secreting SASP products. Recrutied T cells perform immunosurveillance, eliminating damaged and/malignant cells. (b) In the skin of patients with a CDKN2A mutation, multiple senescence‐related defects are present. Both melanocytes and fibroblasts exhibit reduced senescence but are highly susceptible to DNA damage. Senescent fibroblasts secrete reduced levels of SASP products resulting in reduced recruitment of T cells into the skin. This results in reduced immunosurveillance of damaged cells, especially melanocytes that increases the susceptibility of the patients to melanoma. The integrated behaviour of multiple senescent cell types within a single human tissue leading to the development of malignancy is unclear. Patients with Familial Melanoma Syndrome (FMS) have heterozygous germline defects in the CDKN2A gene coding for the cyclin inhibitor p16INK4a. Melanocytes within skin biopsies from FMS patients express significantly less p16INK4a but express higher levels of the DNA‐damage protein γH2AX a than fibroblastic cells. However, patient fibroblasts also exhibit defects since senescent cells do not increase in the skin during ageing and fibroblasts isolated from the skin of patients have increased replicative capacity compared to control fibroblasts in vitro, culminating in abnormal nuclear morphology. Patient derived fibroblasts also secreted less SASP than control cells. Predisposition of FMS patients to melanoma may therefore result from integrated dysregulation of senescence in multiple cell types in vivo. The inherently greater levels of DNA damage and the overdependence of melanocytes on p16 for cell cycle inhibition after DNA damage makes them exquisitely susceptible to malignant transformation. This may be accentuated by senescence‐related defects in fibroblasts, in particular reduced SASP secretion that hinders recruitment of T cells in the steady state and thus reduces cutaneous immunosurveillance in vivo.

Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

Wild-Type P16(Ink4a) Suppresses Cell Growth, Telomerase Activity And Dna Repair In Human Breast Cancer Mcf-7 Cells

Stability and folding of the tumour suppressor protein p16.

Identification of Human and Mouse P19, a Novel CDK4 and CDK6 Inhibitor with Homology to P16ink4

P16 Suppressor Gene and Tumor

P16 Promotes the Growth and Mobility Potential of Breast Cancer Both in Vitro and in Vivo: the Key Role of the Activation of IL-6/JAK2/STAT3 Signaling

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

P16 Promotes Proliferation in Cervical Carcinoma Cells Through CDK6-HuR-IL1A Axis

pRb Inactivation in Mammary Cells Reveals Common Mechanisms for Tumor Initiation and Progression in Divergent Epithelia

Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers

Functional Collaboration Between Different Cyclin-Dependent Kinase Inhibitors Suppresses Tumor Growth with Distinct Tissue Specificity

The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo

Novel Roles For P53 In The Genesis And Targeting Of Tetraploid Cancer Cells

Induction of senescence in human malignant glioma cells by p16INK4A

P57(Kip2), A Structurally Distinct Member of the P21(Cip1) Cdk Inhibitor Family, is A Candidate Tumor-Suppressor Gene

Targeted P16(Ink4a) Epimutation Causes Tumorigenesis and Reduces Survival in Mice

Multiple outcomes of the germline p16INK4a mutation affecting senescence and immunity in human skin

Hydroxymethylated-P16 Allele Is Transcription-Inactive

Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts.